- Sales up 8%, driven by 7% organic growth in
Nutrition and foreign exchange
- Solid volume growth in Human Nutrition; very
strong volume growth in Animal Nutrition
- Nutrition EBITDA: negative impact of vitamin E
and Swiss franc largely offset
- Performance Materials EBITDA: improved on lower
input costs and cost savings despite soft sales
- Strong operating cash flow of €300 million
- 2015 outlook maintained
third quarter |
|
|
|
price / |
exch. |
|
2015 |
2014 |
yoy |
in
€m |
volume |
mix |
rates |
other |
|
|
|
Group |
|
|
|
|
1,945 |
1,794 |
8% |
Sales |
2% |
-1% |
6% |
1% |
287 |
281 |
2% |
EBITDA |
|
|
|
|
|
|
|
Nutrition |
|
|
|
|
1,253 |
1,091 |
15% |
Sales |
6% |
1% |
6% |
2% |
213 |
225 |
-5% |
EBITDA |
|
|
|
|
|
|
|
PM |
|
|
|
|
631 |
638 |
-1% |
Sales |
-3% |
-5% |
7% |
0% |
102 |
87 |
17% |
EBITDA |
|
|
|
|
Commenting on the results, Feike
Sijbesma, CEO/Chairman of the DSM Managing Board, said:
"DSM continued to make good progress in Q3 in both
EBITDA and cash generation. These results
demonstrate the benefits of our focus on improving our operational
performance. We are starting to implement the
previously announced €125-150 million cost reduction program for
the DSM-wide support functions. Tomorrow at our Capital Markets
Day, we will announce our strategy and targets for the coming
years, as well as an additional efficiency and cost reduction
program in Nutrition.
It is increasingly difficult to
predict macro-economic developments. Assuming
no major changes in current market conditions for the remainder of
this year, we maintain our full year outlook
to deliver an EBITDA in 2015 ahead of 2014, the increase mainly
driven by positive foreign exchange effects."
Sales, EBITDA, operating working capital and cash flow refer to
continuing operations.
Key figures
third quarter |
|
|
|
|
|
exch.
rates |
|
2015 |
2014 |
+/- |
|
in €
million |
volume |
price/mix |
other |
|
|
|
|
Net sales |
|
|
|
|
1,253 |
1,091 |
15% |
|
Nutrition |
6% |
1% |
6% |
2% |
631 |
638 |
-1% |
|
Performance Materials |
-3% |
-5% |
7% |
|
42 |
40 |
5% |
|
Innovation Center |
-5% |
-1% |
11% |
|
19 |
25 |
|
|
Corporate Activities |
|
|
|
|
1,945 |
1,794 |
8% |
|
Total continuing operations |
2% |
-1% |
6% |
1% |
157 |
529 |
|
|
Discontinued operations |
|
|
|
|
|
|
|
|
|
|
|
|
|
third quarter |
|
|
|
January - September |
|
|
2015 |
2014 |
+/- |
|
in € million |
2015 |
2014 |
+/- |
|
|
|
|
|
EBITDA |
|
|
|
|
213 |
225 |
-5% |
|
Nutrition |
616 |
650 |
-5% |
|
102 |
87 |
17% |
|
Performance Materials |
294 |
243 |
21% |
|
0 |
-4 |
|
|
Innovation Center |
-8 |
-15 |
|
|
-28 |
-27 |
|
|
Corporate Activities |
-88 |
-94 |
|
|
287 |
281 |
2% |
|
Total continuing operations |
814 |
784 |
4% |
|
3 |
34 |
|
|
Discontinued operations |
94 |
94 |
|
|
|
|
|
|
|
|
|
|
|
123 |
132 |
-7% |
|
Core net profit (continuing operations) |
340 |
360 |
-6% |
|
106 |
113 |
-6% |
|
Net
profit before exceptional items, |
285 |
312 |
-9% |
|
|
continuing operations |
|
36 |
93 |
-61% |
|
Net
profit after exceptional items,
total DSM |
65 |
252 |
-74% |
|
|
|
|
|
|
|
|
|
|
0.70 |
0.76 |
-8% |
|
Core EPS (€/share) |
1.95 |
2.08 |
-6% |
|
0.59 |
0.64 |
-8% |
|
Net EPS before exceptional items, continuing operations
(€/share) |
1.61 |
1.78 |
-10% |
|
0.19 |
0.51 |
-63% |
|
Net EPS
after exceptional items,
total DSM (€/share) |
0.33 |
1.41 |
-77% |
|
|
|
|
|
|
|
|
|
|
300 |
252 |
|
|
Cash flow from continuing operations |
487 |
387 |
|
|
113 |
87 |
|
|
Capital expenditures continuing operations
(cash, net of customer funding) |
321 |
269 |
|
|
|
|
|
|
Net
debt |
2,395 |
2,420 |
* |
|
|
|
|
|
*
year-end 2014 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
In this report:
-
'Organic sales growth' is the
total impact of volume and price/mix;
-
'Discontinued operations'
comprises net sales and operating profit (before depreciation and
amortization) of DSM Pharmaceutical Products up to and including 10
March 2014 as well as DSM Fibre Intermediates and DSM Composite
Resins up to and including 31 July 2015;
-
'Core net profit' is the net
profit from continuing operations before exceptional items and
before acquisition related (intangible) asset
amortization.
Note: all tables are available in the attached
Press release-PDF
Review by cluster
Nutrition
Q3 sales increased 15%, driven by very strong
volume growth in Animal Nutrition & Health and solid volume
developments in Human Nutrition & Health. As a result of higher
prices for some vitamins and other, partly in-sourced, ingredients,
the price/mix-effect was slightly positive despite lower
vitamin E prices.
Q3 EBITDA was 5% lower at €213 million versus Q3 2014. Good volume
growth and overall positive foreign exchange rates largely offset
the negative impact of lower vitamin E prices (of more than €30
million). Positive foreign exchange rates effects mainly associated
with the US dollar were partly offset by the negative impact of the
Swiss franc, the Brazilian real and the Chinese renminbi. The
weakening of the Brazilian real, to which DSM is exposed mainly via
its Tortuga business, had a negative EBITDA impact of ~€5
million.
Animal Nutrition & Health
Volume: Q3 showed very strong volume growth driven
by the premix activities and specialty products in Europe and Latin
America. Although underlying business conditions in the global
animal feed markets are expected to remain favorable, going forward
DSM will face tougher comparative figures for organic growth as
from Q4 2014.
Price: As in the first half of this year, the
price development compared to Q3 2014 was a combination of
significantly lower vitamin E prices and higher prices for a range
of other products. Since a substantial part of these other products
are in-sourced, these increased prices only have limited benefit at
EBITDA level.
Human Nutrition & Health
Volume: DSM delivered solid volume growth in spite
of the continued soft environment in several key market segments.
The dietary supplements businesses continued to show good growth in
Europe and Asia and an ongoing mixed picture in the US where sales
of fish oil and (multi) vitamin based supplements declined in
Q3.
I-Health, DSM's B2C business, continued to deliver double-digit
growth. Conditions in the Food & beverage segment are unchanged
with good sales development in Europe and Asia and ongoing weak
sales in North and South America. Markets for Infant Nutrition are
stable, although DSM's sales were relatively weak in Q3 due to
timing of orders.
Price: Prices were slightly lower versus Q3 2014
mainly as a result of lower vitamin E prices and some mix
effects.
Food Specialties
Q3 showed good volume growth in Enzymes and
Cultures. Also the yeast extract-based savory business is
performing increasingly well.
Performance Materials
Sales in Q3 decreased by 1%
compared to Q3 2014 as a result of overall soft volumes, although
strong in specialties, and lower prices reflecting lower input
costs.
In DSM Engineering Plastics volumes were slightly
down. PA6 polymers sales were weak, amplified by restricted product
availability due to temporary production issues. Compounds and
specialty products showed good volume growth.
In DSM Resins and Functional Materials volumes
declined due to weak demand. Lower prices reflected lower input
costs and a less favorable mix. The market environment for the UV
curable coating resins business of DSM AGI in Asia remained
difficult.
DSM Dyneema delivered
modest organic growth versus Q3 2014 mainly due to timing of orders
in comparison with Q3 2014.
EBITDA in Performance
Materials for the quarter increased by 17% versus Q3 2014. On a
structural base, good margin management and efficiency & cost
savings programs over recent years contributed positively. The
increase in EBITDA was, however, also enhanced by positive foreign
exchange effects as well as temporarily strong margin improvements
due to low input costs.
EBITDA of DSM Engineering Plastics was
substantially up due to higher margins and lower costs.
EBITDA of DSM Resins and Functional Materials was
materially up due to continued good margins and lower costs.
DSM Dyneema showed solid EBITDA growth.
Innovation Center
Sales: DSM Biomedical continues to operate in a
challenging US market.
EBITDA in Q3 improved compared to Q3 2014 driven
by a stronger focus in the innovation activities, cost savings and
positive currency developments.
Corporate Activities
EBITDA in Q3 2015 was in line
with the average quarterly run-rate as well as Q3 2014.
Key joint ventures and associates
DSM Sinochem Pharmaceuticals
(50% DSM) showed a solid financial performance in Q3
supported by favorable exchange rate effects.
DPx holdings (49%
DSM): DPx showed a solid performance. Margin was in line
with previous quarters. On 8 June 2015 DPx, to be renamed Patheon,
has filed a registration statement on Form S-1 with the United
States Securities and Exchange Commission relating to the proposed
initial public offering of its common stock. The timing of the
offering as well as the number of shares to be offered and the
price range for the offering have not yet been determined.
ChemicaInvest (35% DSM): Sales in Q3 were lower
than last year, with lower caprolactam sales coming from a loss in
production following an outage in China and low feedstock
costs.
Discontinued operations
Polymer Intermediates
and Composite Resins
Discontinued operations comprises net sales and
operating profit of DSM Fibre Intermediates and DSM Composite
Resins up to and including 31 July 2015. From that date onwards
their activities have been transferred to ChemicaInvest.
Financial overview Exceptional items
Exceptional items in the
third quarter included non-cash impairment charges of €25 million
related to the obsolescence of certain IT assets as a consequence
of outsourcing and equipment no longer being used. A charge of €15
million was recognized for the devaluation of financial assets in
Venezuela. Restructuring costs and related expenses amounted to €36
million, whilst acquisition related costs and other items were €12
million. Due to these charges a tax benefit of €23 million could be
recognized resulting in a total after tax impact of €65 million.
Associates reported exceptional items of €6 million after tax.
Net profit
Financial income and expense
in Q3 2015 amounted to -€28 million compared to -€26 million in Q3
2014.
The effective tax rate in Q3
2015 remained 18%, equal to the full year 2014.
Net profit from continuing
operations, before exceptional items in Q3 2015 amounted to
€106 million compared to €113 million in Q3 2014.
Net earnings per ordinary share
(continuing operations, before exceptional items) amounted to
€0.59 in Q3 2015 compared to €0.64 in Q3 2014.
Cash flow, capital expenditure and financing
Cash provided by operating
activities from continuing operations in Q3 2015 was €300
million (Q3 2014: €252 million).
Operating working capital
(continuing operations) expressed as a percentage of annualized
sales amounted to 24.9% compared to 26.3% at year-end 2014, in line
with DSM's ambition to further reduce operating working capital. In
Nutrition, operating working capital as a percentage of annualized
sales declined from 34% at year-end 2014 to 32%. The operating
working capital in absolute terms increased by €32 million from
€1,903 million at year-end of 2014 to €1,935 million at the end of
Q3 2015.
Cash used for capital expenditure
net of customer funding (continuing operations) amounted to
€113 million in Q3 2015 compared to €87 million in Q3 2014.
Net debt decreased by €468
million compared to Q2 2015, reflecting the good operating cash
flow and a positive development in mark-to-market value of
financial derivatives held as well as the proceeds from the sale of
the Polymer Intermediates and Composite Resins activities of €282
million.
Outlook 2015
The volatility in currencies, including the
strengthening of the Swiss franc and the US dollar against the
Euro, and the recent weakening of the Brazilian real will have a
mixed effect on DSM's 2015 results compared to 2014. Based on
current exchange rates and the 2015 hedge effects, an overall
annual positive impact on 2015 EBITDA is estimated at approximately
€35 million.
The negative price impact of vitamin E on DSM's
2015 EBITDA is estimated to be approximately €100 million compared
to 2014.
It is increasingly difficult to predict the
macro-economic developments. Assuming current market conditions
will continue for the remainder of the year, DSM maintains its full
year outlook: DSM aims to deliver an EBITDA in 2015 ahead of 2014,
the increase mainly driven by positive foreign exchange
effects.
Additional information
Today DSM will hold a conference call for
investors and analysts from 09.00 to 9.45 CET. Details on how to
access this call can be found on the DSM website, www.dsm.com.
Tomorrow, 4 November 2015, DSM will issue a press
release at 7.15 CET on the information to be discussed at
tomorrow's Capital Markets Day, where DSM will update the markets
on DSM's strategy and targets. DSM will organize a conference call
for the media tomorrow on both the Q3 results and the highlights of
the Capital Markets Day from 09.00 AM to 09.30 AM CET. Details on
how to access this call can be found on the DSM website,
www.dsm.com. The DSM Capital Markets Day can be followed live via
Video webcast from 13.30-19.00 hrs (CET). The presentations can be
found on www.dsm.com as from 13.30 hrs (CET).
Important dates
Capital Markets Day
Wednesday, 4 November
2015
Full year results 2015
Wednesday, 17 February 2016
Report for the first quarter of 2016
Tuesday, 26 April 2016
Annual General Meeting of Shareholders 2016
Friday, 29 April 2016
Report for the second quarter of 2016
Tuesday, 2 August
2016
Report for the third quarter of 2016
Thursday, 3 November 2016
Heerlen, 3 November 2015
The Managing Board
Feike Sijbesma, CEO/Chairman
Geraldine Matchett, CFO
Stephan Tanda
Dimitri de Vreeze
DSM - Bright Science.
Brighter Living.(TM)
Royal DSM is a global science-based company active
in health, nutrition and materials. By connecting its unique
competences in Life Sciences and Materials Sciences DSM is driving
economic prosperity, environmental progress and social advances to
create sustainable value for all stakeholders simultaneously. DSM
delivers innovative solutions that nourish, protect and improve
performance in global markets such as food and dietary supplements,
personal care, feed, medical devices, automotive, paints,
electrical and electronics, life protection, alternative energy and
bio-based materials. DSM and its associated companies deliver
annual net sales of about €10 billion with approximately 25,000
employees. The company is listed on Euronext Amsterdam. More
information can be found at www.dsm.com.
Or find us on:
For more information:
DSM
Corporate Communications
Herman Betten
tel. +31 (0) 45 5782017
e-mail media.contacts@dsm.com |
DSM
Investor Relations
Dave Huizing
tel. +31 (0) 45 5782864
e-mail investor.relations@dsm.com |
Presentation to Investors PDF
Press release-PDF
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: DSM N.V. via Globenewswire
HUG#1963533
BNY Mellon Strategic Mun... (NYSE:DSM)
Historical Stock Chart
From Jun 2024 to Jul 2024
BNY Mellon Strategic Mun... (NYSE:DSM)
Historical Stock Chart
From Jul 2023 to Jul 2024